RT001 (Botulinum Toxin Type A) Topical Gel for the Treatment of Lateral Canthal Lines
Revance's lead investigational product, RT001 (botulinim toxin type A) Topical Gel, is designed to reduce crow's feet wrinkles by temporarily relaxing the muscles around the eye. It has demonstrated efficacy and safety in multiple US Phase 2b clinical studies.
While botulinum toxin injections remain the single largest aesthetic procedure performed in the US, injectable toxins are used by only 10% of consumers considering cosmetic procedures.1 Barriers to broader consumer acceptance and further market growth include frozen face, needle aversion, side effects relating to injection, and variable results depending on physician skill. RT001 Topical Gel could remove many of the barriers related to injection and appeals to 80% of consumers considering cosmetic procedures, having the potential to triple the market.2
1 Market numbers based on AGN data, 2007 2 Primary research conducted by GfK Healthcare in December 2009
RT001 demonstrated statistically significant efficacy versus placebo and achieved the primary as well as secondary endpoints in multiple US Phase 2b studies and ex-US studies.
RT001 appears to be well tolerated, with the majority of adverse events being mild, moderate and transient.
